The KCNA1 Gene Episodic Ataxia Type 1 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the KCNA1 gene, which are linked to Episodic Ataxia Type 1 (EA1). EA1 is a rare genetic disorder characterized by brief episodes of ataxia, or lack of muscle coordination, often accompanied by myokymia (involuntary muscle twitching). These episodes can be triggered by stress, sudden movements, or physical exertion.
The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic alterations in the KCNA1 gene. Identifying these mutations can confirm a diagnosis of EA1, enabling targeted management and treatment strategies for affected individuals.
The cost of the KCNA1 Gene Episodic Ataxia Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the relevant genetic mutations, offering invaluable insights for patients and their families. By confirming a diagnosis, the test can facilitate informed decisions regarding treatment options, potential lifestyle adjustments, and genetic counseling for family planning.
The CACNA1A gene episodic ataxia type 2 genetic test is a specialized diagnostic tool designed to identify mutations in the CACNA1A gene, which is known to cause episodic ataxia type 2 (EA2). EA2 is a rare, inherited neurological disorder characterized by episodes of ataxia (lack of muscle coordination), vertigo, and, in some cases, migraine. The condition is autosomal dominant, meaning a mutation in just one of the two copies of the gene can lead to the disorder.
The test is conducted at DNA Labs UAE, a leading facility in genetic testing and analysis. It involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then examined for specific mutations in the CACNA1A gene that are associated with EA2. This genetic testing is crucial for accurate diagnosis, allowing for appropriate management and treatment of the condition.
The cost of the CACNA1A gene episodic ataxia type 2 genetic test at DNA Labs UAE is 4400 AED. While the price may seem significant, the test provides invaluable information for affected individuals and their families, offering insights into the genetic basis of their condition and guiding decisions regarding treatment and genetic counseling.
The CACNB4 Gene Episodic Ataxia Type 5 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, aimed at identifying mutations in the CACNB4 gene, which are associated with Episodic Ataxia Type 5 (EA5). EA5 is a rare genetic disorder characterized by intermittent episodes of ataxia, or lack of voluntary coordination of muscle movements, including gait abnormality, as well as other potential symptoms such as vertigo, dysarthria, and nystagmus. The CACNB4 gene encodes a crucial subunit of the voltage-dependent calcium channel, playing a vital role in the proper functioning of neuronal cells. Mutations in this gene can disrupt calcium signaling, leading to the symptoms observed in EA5.
This genetic test is crucial for individuals exhibiting symptoms suggestive of episodic ataxia or for those with a family history of the condition, as it provides a definitive diagnosis by identifying the presence of specific mutations in the CACNB4 gene. Early and accurate diagnosis can aid in the management of symptoms and in making informed decisions regarding treatment and lifestyle adjustments.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the CACNB4 Gene Episodic Ataxia Type 5 Genetic Test is 4400 AED. The process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect mutations in the CACNB4 gene. Results from this test can provide valuable insights for patients and their families, guiding healthcare decisions and potentially improving quality of life for those affected by EA5.
The SLC1A3 Gene Episodic Ataxia Type 6 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the SLC1A3 gene, which are linked to Episodic Ataxia Type 6 (EA6). Episodic Ataxia is a neurological condition characterized by sudden attacks of ataxia (loss of control of body movements) along with other potential symptoms such as vertigo, dizziness, and headaches. EA6, a subtype of this condition, is specifically associated with mutations in the SLC1A3 gene.
This genetic test is crucial for individuals showing symptoms suggestive of EA6, as it helps in confirming the diagnosis, thereby enabling healthcare providers to tailor treatment and management plans more effectively. The procedure involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for the presence of mutations in the SLC1A3 gene.
The cost of the SLC1A3 Gene Episodic Ataxia Type 6 Genetic Test at DNA Labs UAE is set at 4400 AED. The test is conducted with high precision and accuracy, employing advanced genetic sequencing technologies to ensure reliable results. Given the specialized nature of this test and its significance in the accurate diagnosis and management of EA6, the investment is considered valuable for affected individuals and their families.
The SCN10A gene plays a crucial role in the human body by encoding the Nav1.8 sodium channel, which is essential for the transmission of pain signals in the peripheral nervous system. Mutations in the SCN10A gene can lead to episodic pain syndrome type 2, a familial condition characterized by recurrent episodes of severe pain without obvious physical causes. This condition underscores the importance of precise genetic diagnostics for individuals experiencing unexplained episodic pain.
The genetic test for episodic pain syndrome type 2, associated with the SCN10A gene, is a sophisticated diagnostic tool available at DNA Labs UAE. Priced at 4400 AED, this test offers individuals and families the opportunity to identify the genetic basis of their condition, paving the way for personalized management strategies and potential treatments. Conducted in a state-of-the-art facility, the test involves analyzing the patient's DNA to detect mutations in the SCN10A gene that are linked to the syndrome.
By opting for this genetic test, patients gain valuable insights into their condition, allowing for a more targeted approach to pain management and therapy. It also provides families with the information needed for genetic counseling, especially for those planning to have children and concerned about the hereditary nature of episodic pain syndrome type 2. DNA Labs UAE ensures confidentiality, accuracy, and support throughout the testing process, making it a trusted choice for genetic diagnostics in the region.
The SCN11A gene episodic pain syndrome type 3 familial genetic test is a specialized diagnostic procedure designed to identify mutations in the SCN11A gene, which are linked to the development of Familial Episodic Pain Syndrome Type 3 (FEPS3). This condition is characterized by episodes of severe pain without an apparent cause, affecting individuals from the same family, indicating a genetic basis. The SCN11A gene plays a crucial role in the transmission of pain signals in the nervous system, and mutations can lead to abnormal pain perception.
Conducted at DNA Labs UAE, a leading facility in genetic testing, this test offers a critical insight for affected individuals and their families, providing a definitive diagnosis of FEPS3. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed for specific genetic alterations in the SCN11A gene that are known to cause the syndrome.
The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the expertise required to interpret the results. Obtaining a diagnosis through this test can be pivotal for affected individuals, as it not only helps in understanding the cause of their pain but also guides the management and treatment strategies to mitigate the symptoms, improving their quality of life. Additionally, the results can inform family planning decisions for those carrying the mutation.
The SCN9A Gene Erythermalgia Primary Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the SCN9A gene, which are associated with Primary Erythermalgia (PE), also known as Primary Erythromelalgia. This rare condition is characterized by episodes of burning pain, redness, and swelling in the extremities, triggered by warm temperatures or mild physical activity. The test is crucial for confirming a clinical diagnosis of PE, enabling personalized treatment plans, and providing valuable information for family planning. Priced at 4400 AED, the test involves collecting a DNA sample, typically through a blood draw, and analyzing it for specific genetic mutations in the SCN9A gene. Results from this test can help in the management of symptoms and improve the quality of life for individuals with Primary Erythermalgia. DNA Labs UAE ensures a comprehensive and confidential testing process, guided by genetic counselors and medical professionals.
Ethylmalonic Encephalopathy (EE) is a rare genetic disorder characterized by progressive neurological impairment, metabolic abnormalities, and, in many cases, early mortality. The condition is caused by mutations in the ETHE1 gene, which plays a crucial role in the metabolic process. The disorder manifests with a range of symptoms including developmental delay, seizures, chronic diarrhea, and orthostatic acrocyanosis, making early and accurate diagnosis vital for management and treatment planning.
The ETHE1 Gene Ethylmalonic Encephalopathy Genetic Test is a specialized diagnostic tool designed to detect mutations in the ETHE1 gene, confirming the diagnosis of EE. This test is critical for families with a history of the disorder or where EE is suspected based on clinical symptoms. Early diagnosis through genetic testing can facilitate timely intervention and potentially improve outcomes.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers a comprehensive analysis of the ETHE1 gene. DNA Labs UAE employs state-of-the-art technology and adheres to stringent quality control measures to ensure the accuracy and reliability of test results. The cost of the ETHE1 Gene Ethylmalonic Encephalopathy Genetic Test is 4400 AED, reflecting the advanced nature of the testing process and the specialized expertise required to interpret the results.
Families and individuals undergoing this test at DNA Labs UAE can expect professional guidance throughout the testing process, from sample collection to result interpretation. The facility's genetic counselors are available to discuss the implications of test outcomes and support patients in making informed decisions about their health and management options.
The HOXB1 Gene Facial Paresis Type 3 Genetic Test is a specialized diagnostic tool used to identify mutations in the HOXB1 gene, which are associated with Facial Paresis Type 3, a rare genetic disorder. This condition is characterized by the partial or complete inability to move the muscles of the face, due to developmental issues affecting the facial nerves. The test is crucial for early detection and management of the disorder, allowing for appropriate interventions and support to be provided to affected individuals.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed for specific genetic alterations in the HOXB1 gene. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the genetic mutation responsible for the condition.
By opting for the HOXB1 Gene Facial Paresis Type 3 Genetic Test, individuals at risk or families with a history of the disorder can gain valuable insights into their genetic makeup, enabling informed healthcare decisions and personalized medical care to mitigate the effects of this challenging condition.
The FAT1 gene, associated with the development of a Facioscapulohumeral dystrophy-like phenotype, is the focus of specialized genetic testing offered by DNA Labs UAE. This test aims to identify mutations in the FAT1 gene that could lead to symptoms and clinical manifestations resembling Facioscapulohumeral muscular dystrophy (FSHD), a genetic disorder characterized by progressive muscle weakness and atrophy, primarily affecting the face, shoulder blades, and upper arms.
DNA Labs UAE provides this comprehensive genetic analysis at a cost of 4400 AED. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the FAT1 gene. This precise genetic testing is crucial for individuals showing symptoms akin to FSHD, as it helps in confirming a diagnosis, understanding the risk of passing the condition to offspring, and guiding treatment and management decisions. By identifying specific genetic mutations, healthcare providers can offer more personalized care, potentially improving the quality of life for those affected by this condition.
